Health ❯ Healthcare ❯ Oncology

Clinical Trials

Adverse Effects Metastatic Colorectal Cancer Patient Outcomes Phase 3 Trials Phase 2 Trials Bladder Cancer Precision Medicine Metastatic Castration-Sensitive Prostate Cancer Trial Results Drug Development Health-Related Quality of Life Pancreatic Cancer Silevertinib Lung Cancer EGFR L858R-Mutated NSCLC Mantle Cell Lymphoma Pediatric Oncology Abstracts ESMO Congress 2025 Non-Small Cell Lung Cancer DESTINY-Breast05 Trial Breast Cancer HER2-positive Breast Cancer Gastroenteropancreatic Neuroendocrine Tumors Combination Therapies Treatment Efficacy Drug Treatments Innovative Therapies ADRIATIC Trial Small Cell Lung Cancer IMforte Trial NRG-LU005 Study Immunotherapy Regorafenib AI in Healthcare Glioblastoma Temozolomide KEYNOTE-B15/EV-304 Trial Muscle-Invasive Bladder Cancer NAPOLI 3 Study Gastric Cancer Melanoma Diffuse Large B-Cell Lymphoma Patient Response Therapeutic Efficacy Cancer Research Emerging Therapies Phase I Trials Phase II Trials

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Next steps center on Phase 3 confirmation, with full data pending.

Epcoritamab Improves PFS but Not OS in Phase 3 DLBCL Trial

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

Mount Sinai Deploys PRISM AI to Match Cancer Patients to Trials Systemwide

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer